Disease progression model of 4T1 metastatic breast cancer

被引:0
|
作者
Liang Yang
Ling Yong
Xiao Zhu
Yaoyao Feng
Yu Fu
Daming Kong
Wei Lu
Tian-yan Zhou
机构
[1] Peking University,Beijing Key Laboratory of Molecular Pharmaceutics and New Drug Delivery System, Department of Pharmaceutics, School of Pharmaceutical Sciences
[2] University of Otago,School of Pharmacy
来源
Journal of Pharmacokinetics and Pharmacodynamics | 2020年 / 47卷
关键词
Disease progression model; 4T1; Breast cancer; Lung metastasis; Mathematical model;
D O I
暂无
中图分类号
学科分类号
摘要
Cancer metastasis is the main cause of death in various types of cancer. However, in the field of pharmacometrics, cancer disease progression models focus on the growth of primary tumors with tumor volume or weight as target values, while the metastasis process is less mentioned. We propose a series of mathematical models to quantitatively describe and predict the disease progression of 4T1 breast cancer in the aspect of primary breast tumor, lung metastasis and white blood cell. The 4T1 cells were injected into breast fat pad of female BALB/c mice to establish an animal model of breast cancer metastasis. The number and volume of lung metastases at different times were measured. Based on the above data, a disease progression model of breast cancer lung metastasis was established and parameter values were estimated. The white blood cell growth and the primary tumor growth of 4T1 mouse are also modeled. The established models can describe the lung metastasis of 4T1 breast cancer in three aspects: (1) the increase in metastasis number; (2) the growth of metastasis volume; (3) metastasis number-size distribution at different time points. Compared with the prior metastasis models based on von Forester equation, our models distinguished the growth rate of primary tumor and metastasis and got parameter values for 4T1 mouse model. And the current models optimized the metastasis number-size distribution model by utilizing logistic function instead of the prior power function. This study provides a comprehensive description of lung metastasis progression for 4T1 breast cancer model, as well as an alternative disease progression model structure for further pharmacodynamics modeling.
引用
收藏
页码:105 / 116
页数:11
相关论文
共 50 条
  • [21] Pulmonary and systemic nitric oxide deficiency in the early phase of lung metastasis in 4T1 metastatic breast cancer murine model
    Proniewski, Bartosz
    Kij, Agnieszka
    Smeda, Marta
    Buczek, Elzbieta
    Kieronska, Anna
    Kus, Kamil
    Przyborowski, Kamil
    Derszniak, Katarzyna
    Matyjaszczyk, Karolina
    Jasztal, Agnieszka
    Stojak, Marta
    Walczak, Maria
    Wietrzyk, Joanna
    Chlopicki, Stefan
    FREE RADICAL BIOLOGY AND MEDICINE, 2018, 128 : S72 - S73
  • [22] Combination immunotherapy with extract of heated 4T1 and naloxone in mouse model of breast cancer
    Jahangiri, Shervin
    Abtahi Froushani, Seyyed Meysam
    Delirezh, Norouz
    TURKISH JOURNAL OF MEDICAL SCIENCES, 2016, 46 (02) : 518 - 523
  • [23] FXYD5 (dysadherin) may mediate metastatic progression through regulation of the β-Na+-K+-ATPase subunit in the 4T1 mouse breast cancer model
    Lubarski-Gotliv, Irina
    Dey, Kuntal
    Kuznetsov, Yuri
    Kalchenco, Vecheslav
    Asher, Carol
    Garty, Haim
    AMERICAN JOURNAL OF PHYSIOLOGY-CELL PHYSIOLOGY, 2017, 313 (01): : C108 - C117
  • [24] Biodistribution and Imaging Evaluation of Cyclic Peptide RGD in 4T1 Breast Cancer Model
    Chen, M.
    Huang, Y.
    Chen, S.
    Chen, L.
    Li, M.
    Chang, C.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2018, 45 : S679 - S680
  • [25] The highly metastatic 4T1 breast carcinoma model possesses features of a hybrid epithelial/mesenchymal phenotype
    Herndon, Mary E.
    Ayers, Mitchell
    Gibson-Corley, Katherine N.
    Wendt, Michael K.
    Wallrath, Lori L.
    Henry, Michael D.
    Stipp, Christopher S.
    DISEASE MODELS & MECHANISMS, 2024, 17 (09)
  • [26] Application of a count data model to evaluate the anti-metastatic efficacy of QAP14 in 4T1 breast cancer allografts
    Guo, Yuchen
    Yong, Ling
    Yao, Qingyu
    Han, Mengyi
    Xue, Junsheng
    Jian, Weizhe
    Zhou, Tianyan
    JOURNAL OF THEORETICAL BIOLOGY, 2023, 557
  • [27] CSFR-1R a potential therapeutic target in 4T1 xenograft breast cancer model
    Elia, Jeanne
    Zhang, Hong
    Wen, Chiaokai
    Yang, Xifeng
    CANCER RESEARCH, 2020, 80 (16)
  • [28] Doxorubicin-induced Immunogenic Cell Death Impairs Tumor Progression and Distant Metastasis in a 4T1 Breast Cancer Tumor Model
    Cardador, Camila Magalhaes
    de Castro, Thais Bergmann
    de Castro, Raffael Junio Araujo
    Bocca, Anamelia Lorenzetti
    Camargo, Luana Cristina
    Pacheco, Thyago Arruda
    Muehlmann, Luis Alexandre
    Longo, Joao Paulo Figueiro
    CURRENT PHARMACEUTICAL DESIGN, 2024, 30 (31) : 2493 - 2504
  • [29] Differential Proteome Analysis Identifies TGF-β-Related Pro-Metastatic Proteins in a 4T1 Murine Breast Cancer Model
    Sato, Misako
    Matsubara, Tsutomu
    Adachi, Jun
    Hashimoto, Yuuki
    Fukamizu, Kazuna
    Kishida, Marina
    Yang, Yu-an
    Wakefield, Lalage M.
    Tomonaga, Takeshi
    PLOS ONE, 2015, 10 (05):
  • [30] Zoledronic acid inhibits visceral metastases in the 4T1/luc mouse breast cancer model
    Hiraga, T
    Williams, PJ
    Ueda, A
    Tamura, D
    Yoneda, T
    CLINICAL CANCER RESEARCH, 2004, 10 (13) : 4559 - 4567